RF07026

RF07026 is a small molecule, selective kappa opioid receptor (KOR) agonist developed by Yichang Renfu Pharmaceutical, a subsidiary of Humanwell Healthcare. It is primarily being investigated for the management of moderate to severe postoperative pain. The drug is designed to target peripheral kappa opioid receptors to provide effective analgesia while minimizing the central nervous system (CNS) side effects typically associated with mu-opioid receptor agonists, such as respiratory depression and addiction, or non-selective KOR agonists, such as dysphoria and hallucinations. RF07026 has advanced into Phase 2 clinical trials in China, demonstrating its potential as a safer alternative for acute pain management in clinical settings.